47 Results
Sort By:
Published on August 27, 2024
A new nasal COVID-19 vaccine is ready for clinical trials, said K. Anand Kumar, managing director of Indian Immunologicals and one of the co-authors of a new report on the vaccine. Called CDO-7N-1, it “induces robust mucosal and systemic neutralizing antibody and T-cell subset responses, in mice, hamsters, and macaques…
Published on October 16, 2023
Codagenix’s nasal vaccine for COVID-19 delivered positive results in a Phase I trial, according to a presentation at IDWeek’s 2023 annual meeting last week. In tandem, the U.S. awarded almost $20M in funding for nasal COVID-19 development. CastleVax and Codagenix, the only two companies that have delivered Phase I results…
Published on March 28, 2023
A team of researchers at the University of Helsinki, Finland, report they have developed a molecule that can be administered nasally to prevent the development of COVID-19 symptoms by all known variants of the SARS-CoV-2 virus. The team noted that the molecule could be a tool used in future pandemics…
Published on March 9, 2023
A pilot trial led by scientists at Brigham and Women’s Hospital in Boston, MA has shown decreased levels of inflammatory markers in patients with COVID-19 when using the monoclonal antibody “Foralumab.” The research published in Proceedings of the National Academy of Sciences, shows that nasal administration of the drug Foralumab,…
Published on December 4, 2020
Eight to 10 years ago, Bill Gates asked gene therapy pioneer James M. Wilson, MD, PhD, whether his lab’s expertise in using adeno-associated virus (AAV) vectors could be applied toward fighting a pandemic. At the time, the Bill & Melinda Gates Foundation had approached Wilson, director of the Gene Therapy Program…
Published on April 26, 2024
There’s new evidence the COVID-19 mRNA vaccines don’t provide much mucosal immunity, according to a team of French researchers. In a study that included more than 400 patients, there was some mucosal immunity provided by these vaccines, but previously infected people had a greater response. This suggests that new approaches,…
Published on December 20, 2023
Protection against COVID-19 may be improved by delivering booster shots directly to the respiratory tract—the primary site of entry for SARS-CoV-2 infection, research from Beth Israel Deaconess Medical Center (BIDMC) suggests. In a study using macaques, this team found that boosters given via inhaler, which delivers treatment straight to the…
Published on June 1, 2023
A molecular “decoy” provided long-term protection from SARS-CoV-2 infection in mice, in a new study. The researchers created a version of ACE2, the surface protein the virus attaches in peoples’ airways. The free-floating decoy binds the virus, soaking it up before it can infect the airway. Treatment with the decoy,…
Published on February 28, 2023
A new molecular testing method in the early stages of development by researchers at the Flatiron Institute’s Center for Computational Biology (CCB) can potentially identify COVID-19 infections just hours after exposure with near perfect accuracy, much earlier than current tests can detect the virus. According to Frank Zhang a research…
Published on December 22, 2021
A comprehensive single-cell study comparing the response to SARS-CoV-2 infection in adults and children shows children have a stronger innate immune respiratory response to the virus than adults, allowing them to effectively stop the infection at an early stage. As the COVID-19 pandemic has progressed, it has become clear that…
Published on November 18, 2021
A large, long-term study of the impacts of COVID-19 on children has enrolled its first participant at the National Institutes of Health’s Clinical Center in Bethesda, Maryland. The study, which is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),…
Published on September 22, 2021
Eighteen months into the pandemic, the need for effective treatments against COVID-19 remains as great as ever. Now, a team of researchers from the Rosalind Franklin Institute demonstrates that neutralizing single domain antibodies (nanobodies), has significant potential. The unique antibody produced by llamas is small, stable, and could possibly be administered…
Published on August 19, 2021
One of the many unanswered questions of the pandemic is why children are more protected from infection from SARS-CoV-2, and also why when they do become infected they have a reduced risk of developing severe COVID-19. Now, a team of researcher has compared the single-cell transcriptional landscape of the upper…
Published on August 17, 2021
The role of nasal bacteria in virus-specific adaptive immunity is a major question with a material impact on development of intranasal vaccines for respiratory diseases such as COVID-19 and flu. A new study from researchers at the University of Tokyo made some key findings about this process. The researchers found…
Published on May 18, 2021
Researchers from the University of Illinois at Urbana-Champaign have developed a Scalable and Portable Testing (SPOT) system that uses at type of LAMP amplification to detect COVID-19 quickly, easily and accurately from saliva samples. The prototype device is hand held and battery powered and many parts can be 3D printed.…